Accelerating research and development of new vaccines against tuberculosis
Reviews progress since the 2021 Global TB Vaccine R&D Roadmap and identifies remaining actions needed to accelerate availability, access and uptake of new TB vaccines
Epidemiological impact
Estimating the population impact of new tuberculosis vaccines depending on efficacy against infectious asymptomatic tuberculosis:
Uses a dynamic TB transmission model to estimate how the population impact of future TB vaccines changes depending on whether vaccines prevent progression to infectious symptomatic TB only, all infectious TB, or all TB disease.
Tuberculosis policy should shift focus to population-level interventions for greatest impact
Uses mathematical modelling to compare the population-level health and economic impacts of TB interventions in Brazil, India and South Africa. It highlights mass vaccination and community-wide screening as interventions with the potential for substantial epidemiological impact.
Target Tuberculosis vaccination strategies in the United States
Uses a mathematical model to evaluate targeted TB vaccination strategies in the United States. The study examines which high-risk groups should be prioritised for a future adult TB vaccine, including people living with HIV, people with medical comorbidities, and people born outside the United States
Facing up to reality? What to do if M72/AS01E doses are limited
The Ph3 trial for the vaccine candidate M72/AS01E is underway, and, assuming a
positive result, could be licensed by 2030. Modelling suggested a large potential impact from
introducing M72/AS01E but assumed an unconstrained dose supply. However, at least initially, it is
likely that M72/AS01E will be supply-constrained. We estimated the effect of decisions surrounding
the allocation of constrained doses on the potential global impact of M72/AS01E
Advancing evidence-informed in-country decision-making for new TB vaccine introduction: A responsive and integrated vaccine modelling approach from India
As new TB vaccines move into late-stage development, it is imperative for high-burden
countries like India to ensure timely and effective evidence-generation to inform decision-making
and accelerate vaccine development and introduction. To enable this, an in-country vaccine
mathematical modelling effort has been initiated in India.
TBVacMod
Estimate the health impact of introducing a prevention of disease vaccine for adult and adolescents in moderate to high TB burden countries. Explore different vaccine introduction scenarios based on input from country stakeholders, including national TB program and immunization program officials, on priority groups for vaccination and likely vaccine coverage. The project's key questions include: 1) who are the priority groups in different countries and what is expected level of vaccine coverage in those groups
2) how will vaccine impact differ in different introduction scenarios (vary age, priority group, coverage)
New Tuberculosis vaccines for people with HIV
Mathematical modelling study assessing how different strategies for vaccinating people with and without HIV could reduce TB cases among people with HIV in high HIV/TB burden countries
A model for the epidemiological impact of tuberculosis policy options
Develops a new TB transmission model to help decision-makers comapre the epidemiological impact of different TB interventions and allocate resources. The model incorporates diagnosis, treatment, drug resistance, HIV status, age, and vaccination status, and was calibrated using data from 29 high burden countries. It demonstrates the potential impact of comprehensive TB interventions in Indonesia and Nigeria, including the possible use of a post-exposure TB vaccine
How can new TB vaccines be effectively introduced in Indonesia?
Explores how Indonesia could prepare for and successfully introduce a new adult TB vaccine. It brought together 28 stakeholders form TB, immunisation and international organisations to examine potential target popualtions, delievery strategies, financing , vaccine accpetability, helath system readinessfor vaccine introduction